Trial Profile
A Phase Ib/II Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine or Decitabine in Patients With Acute Myeloid Leukemia or as a Single Agent in Patients With Myelodysplastic Syndrome
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Bemcentinib (Primary) ; Cytarabine; Decitabine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors BerGenBio
- 12 Dec 2023 Results assessing the final efficacy and safety data, as well as pharmacokinetic/pharmacodynamic analysis from part A were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 12 Dec 2023 Results from sub study assessing potential role of TNF alpha and cytotoxic immune cells in the successful application of bemcentinib-LDAC., presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 14 Nov 2022 According to a BerGenBio media release, Company expects to provide results following database lock and subsequent data analysis in 1H of 2023.